Advanced Search

 

Study ID Status Title Patient Level Data
200820 Completed A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
200858 Recruiting A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects with Relapsed/Refractory Small Cell Lung Carcinoma
200860 Completed Clinical assessment of fluticasone propionate/ salmeterol xinafoate HFA MDI in 6-month to 4-year-old Japanese patients with bronchial asthma
200862 Completed A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects with Severe Eosinophilic Asthma on Markers of Asthma Control
200869 Recruiting The Burden of Rhinitis Symptoms in Chinese Patients with Allergic Rhinitis
200870 Recruiting The Mepolizumab Pregnancy Exposure Study: a VAMPSS post marketing surveillance study of Mepolizumab safety in pregnancy
200883 Recruiting Evaluation Of Use of Belimumab in Clinical Practice SEttings (OBSErve) Observations from Spain
200884 Completed A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers
200894 Not yet recruiting Study 200894: A double-blind, double-dummy, randomized, parallel group, placebo-controlled superiority study to evaluate the efficacy and safety of tafenoquine (SB-252263, WR238605) co-administered with dihydroartemisinin-piperaquine (DHA-PQP) for the radical cure of Plasmodium vivax malaria
200896 Active not recruiting Reasons and Consequences for Discontinuation and Adherence with Daily Glucagon-like Peptide-1 Therapies in Type 2 Diabetes Mellitus Patients in the United States
200901 Completed A Phase I, Open label, Randomized, Three period, Fixed Sequence Crossover study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901)
200902 Completed A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
200909 Recruiting A single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1550188 in Chinese subjects with Systemic Lupus Erythematosus (SLE)
200911 Not yet recruiting A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicistat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-naive adults
200912 Terminated A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 with and without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects
200919 Completed An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects with BRAF V600 Mutation Positive Tumors
200920 Completed Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application under non-occlusive condition in Healthy Japanese Subjects
200921 Completed An open-label, randomised, cross-over, two cohort, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the delivery of salbutamol and to compare the pharmacokinetic profile with the MDI and Diskus presentations.
200926 Active not recruiting A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects with Refractory, Moderate or More Severe Aplastic Anemia
200928 Not yet recruiting A multi-centre, randomised, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of GSK3050002 in subjects with psoriatic arthritis
200934 Completed An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects with Type 2 Diabetes Mellitus
200938 Not yet recruiting A randomized, double-blind, placebo controlled, multi-center study to evaluate the pharmacokinetics, safety and efficacy of albiglutide for the treatment of type 2 diabetes mellitus in pediatric patients
200939 Completed An open-label, randomised, cross-over, single dose study in healthy volunteers to evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) with four different formulations for the delivery of fluticasone furoate and to compare the pharmacokinetic profile with the fluticasone furorate ELLIPTA presentation
200940 Completed An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (Gasmotin) in Healthy Adult Human Subjects Under Fasting Conditions
200942 Recruiting A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects with End Stage Renal Disease Undergoing Peritoneal Dialysis

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.